Rumor Mill: Is Volcano Corporation Ripe For A Buyout?

Published: Nov 14, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Diagnostics and stents maker Volcano (NSDQ:VOLC) may be primed for acquisition, with a raft of analysts' groups debating only the timing of a buy. Volcano's stents and stent placement and evaluation technologies could draw buyers from some of medtech's biggest players, such as Medtronic (NYSE:MDT) and Abbott (NYSE:ABT), according to market reports. Engaged Capital, which owns a significant stake in the company, recommended patience, saying the company may garner a higher price if it waits to sell.

Help employers find you! Check out all the jobs and post your resume.

Back to news